A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH07-09-0555
Issue:2008: 99/1 (Jan) pp. 1-248
Pages:215-222

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

Joseph A. Jakubowski1, Christopher D. Payne2, Ying G. Li1, Nagy A. Farid1, John T. Brandt1, David S. Small1, Daniel E. Salazar3, Kenneth J. Winters1
1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA; 2Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, UK; 3Daiichi Sankyo, Inc., Parsippany, NJ, USA

Summary

Platelet inhibition as measured by vasodilator-stimulated phosphoprotein (VASP) and light transmission aggregometry (LTA) have shown concordance following dosing of clopidogrel.No reports have directly compared theVASP assay and LTA at the levels of P2Y12 blockade after loading doses (LDs) of prasugrel or high dose clopidogrel (600 and 900 mg).The aim was to compare theVASP assay and LTA during the loading dose phase of a comparative study of prasugrel and clopidogrel. Prasugrel 60 mg LD/10 mg maintenance dose (MD) and clopidogrel 300 mg/75 mg and 600 mg/75 mg LD/MD regimens were compared in a 3-way crossover study in 41 healthy, aspirin-free subjects. Each LD was followed by seven daily MDs and a 14-day washout period. P2Y12 receptor blockade was estimated using theVASP assay, expressed as platelet reactivity index (VASP-PRI). Platelet aggregation was assessed by light transmission aggregometry (20 and 5 μM ADP).Twenty-four hoursafter prasgurel 60 mg or clopidogrel 300 mg and 600 mg, respectively,VASP-PRI decreased from ~80% to 8.9%, 54.7%, and 39.0 %, and maximal platelet aggregation (MPA) decreased from ~79% to 10.8%, 42.7%, and 31.2%, with an overall VASP:MPA correlation of 0.88 (p<0.01). VASP assay responses after the clopidogrel LDs showed a wider range of values (300 mg: 0–93%; 600 mg: 0–80%) than prasugrel (0–13%); MPA responses followed a similar trend. Pearson’s correlation suggested a strong agreement between VASP and LTA (20 μM ADP) for MPA (r=0.86, p<0.0001).VASP and LTA demonstrated concordance across the response range of P2Y12 receptor blockade following thienopyridine LDs.

Keywords

clopidogrel, VASP, prasugrel, P2Y12, thienopyridine

DOI

http://dx.doi.org/10.1160/TH07-09-0555

You may also be interested in...

1.

Christian Gachet

Thrombosis and Haemostasis 2008 99 3: 466-472

http://dx.doi.org/10.1160/TH07-11-0673

2.

J. A. Jakubowski (1), N. Bourguet (2), D. Boulay-Moine (2), A. Sugidachi (3), S. Yamaguchi (4), P. Barragan (5), C. Zhou (1), M. Moulard (2)

Thrombosis and Haemostasis 2012 107 2: 388-395

http://dx.doi.org/10.1160/TH11-04-0282

3.

Joseph A. Jakubowski1, Christopher D. Payne2, Ying G. Li1, John T. Brandt1, David S. Small1, Nagy A. Farid1, Daniel E. Salazar3, Kenneth J. Winters1

Thrombosis and Haemostasis 2008 99 2: 409-415

http://dx.doi.org/10.1160/TH07-09-0575



Articles

You've 565 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...